Cervical dissecting extravasation of oxaliplatin: A case report.

Oxaliplatin is a chemotherapy drug considered to be an irritant and vesicant. Peripheral extravasation could happen following oxaliplatin chemotherapy administration, but mediastinal or cervical events are rare. The present study focused on the case of a 64-year-old female patient with KRAS-mutated colorectal adenocarcinoma. The patient was prescribed folinic acid, fluorouracil and oxaliplatin chemotherapy via a subcutaneous pump or port-a-cath device, which was inserted into the right subclavian vein. The patient reported a sudden throbbing pain in the chest wall and anterior cervical region. After performing a computed tomography scan, anterior cervical collection and jugular-subclavian venous confluence at the distal end was observed at the venous access site of the subcutaneous port-a-cath device, which extended cranially, dissected cervical planes and forming a hydro-aerial collection in the submaxillary region. Subsequently, the port-a-cath device was removed and a warm dry compress was applied. After 2 weeks, the patient had fully recovered without any sequelae at the cervical level. To the best of the authors' knowledge, this is the first case of cervical extravasation of oxaliplatin reported in the literature to date and will help to manage similar situations.

[1]  X. Qian,et al.  Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts. , 2020, Metallomics : integrated biometal science.

[2]  S. Ho,et al.  A Molecular Perspective , 2019 .

[3]  F. Bahadori,et al.  Management of extravasation of oxaliplatin by mimicking its biotransformation , 2018, Clinical and Translational Oncology.

[4]  N. E. El Saghir,et al.  Overview, prevention and management of chemotherapy extravasation. , 2016, World journal of clinical oncology.

[5]  R. Mader,et al.  Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  S. E. Nielsen,et al.  [Reversible tissue damage after paravasal infusion of oxaliplatin]. , 2015, Ugeskrift for laeger.

[7]  F. Narducci,et al.  Chemotherapy Drug Extravasation in Totally Implantable Venous Access Port Systems: How Effective is Early Surgical Lavage? , 2015, The journal of vascular access.

[8]  T. Hickish,et al.  A midline for oxaliplatin infusion: the myth of safety devices , 2014, BMJ Case Reports.

[9]  A. Margulies,et al.  Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Leon-Ferre,et al.  Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. , 2012, Clinical advances in hematology & oncology : H&O.

[11]  D. Conde-Estévez,et al.  [Update in the management of extravasations of cytocytostatic agent]. , 2012, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[12]  C. Fournier,et al.  Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  M. Saif,et al.  Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.

[14]  Joan Ramon Soler,et al.  Extravasation of oxaliplatin: an infrequent and irritant toxicity , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  R. Wickham,et al.  Vesicant extravasation part II: Evidence-based management and continuing controversies. , 2006, Oncology nursing forum.

[16]  D. Goodsell The molecular perspective: Cisplatin. , 2006, Stem cells.

[17]  M. D. de Lemos,et al.  Management of extravasation of oxaliplatin , 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[18]  H. Hochster,et al.  Oxaliplatin: practical guidelines for administration. , 2004, Clinical journal of oncology nursing.

[19]  P. Reichert,et al.  Extravasations of oxaliplatin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Markman Toxicities of the platinum antineoplastic agents , 2003, Expert opinion on drug safety.

[21]  J. Zalcberg,et al.  A case report of oxaliplatin extravasation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Baur,et al.  Extravasation of Oxaliplatin (Eloxatin®) – Clinical Course , 2000, Oncology Research and Treatment.